Lozano Teresa, Villanueva Lorea, Durántez Maika, Gorraiz Marta, Ruiz Marta, Belsúe Virginia, Riezu-Boj José I, Hervás-Stubbs Sandra, Oyarzábal Julen, Bandukwala Hozefa, Lourenço Ana R, Coffer Paul J, Sarobe Pablo, Prieto Jesús, Casares Noelia, Lasarte Juan J
Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31.
Regulatory T cell (Treg) activity is modulated by a cooperative complex between the transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT interaction is required to repress expression of IL-2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function to Tregs. However, FOXP3 is expressed transiently in conventional CD4(+) T cells upon TCR stimulation and may lead to T cell hyporesponsiveness. We found that a short synthetic peptide able to inhibit FOXP3/NFAT interaction impaired suppressor activity of conventional Tregs in vitro. Specific inhibition of FOXP3/NFAT interaction with this inhibitory peptide revealed that FOXP3 downregulates NFAT-driven promoter activity of CD40L and IL-17. Inhibition of FOXP3/NFAT interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and IL-2, IFN-γ, IL-6, or IL-17 production in response to TCR stimulation. The inhibitory peptide impaired effector T cell conversion into induced Tregs in the presence of TGF-β. Moreover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib or with an antitumor vaccine, respectively. Our results suggest that inhibition of NFAT/FOXP3 interaction might improve antitumor immunotherapies.
调节性T细胞(Treg)的活性由转录因子NFAT与FOXP3(一种Treg的谱系特异性因子)之间的协同复合物调节。FOXP3与NFAT的相互作用对于抑制白细胞介素-2(IL-2)的表达、上调Treg标志物细胞毒性T淋巴细胞相关抗原4(CTLA4)和CD25的表达以及赋予Treg抑制功能是必需的。然而,在T细胞受体(TCR)刺激后,FOXP3在常规CD4(+) T细胞中短暂表达,并可能导致T细胞反应性降低。我们发现一种能够抑制FOXP3/NFAT相互作用的短合成肽在体外损害了常规Treg的抑制活性。用这种抑制性肽特异性抑制FOXP3/NFAT相互作用表明,FOXP3下调了CD40配体(CD40L)和白细胞介素-17(IL-17)的NFAT驱动的启动子活性。抑制FOXP3/NFAT相互作用上调了效应T细胞上CD40L的表达,并增强了T细胞增殖以及对TCR刺激的白细胞介素-2、干扰素-γ(IFN-γ)、白细胞介素-6或白细胞介素-17的产生。在存在转化生长因子-β(TGF-β)的情况下,抑制性肽损害了效应T细胞向诱导性Treg的转化。此外,在体内给予该肽分别与索拉非尼联合或与抗肿瘤疫苗联合时,对携带Hepa129或TC1肿瘤细胞的小鼠显示出抗肿瘤功效。我们的结果表明,抑制NFAT/FOXP3相互作用可能会改善抗肿瘤免疫疗法。